A psychedelic drug development company with a difference

ABOUT US

Funding psilocybin research for a better tomorrow

Founded by Carey and Claudia Turnbull, B. More is a 501(c)(3) non-profit, clinical-stage biopharmaceutical company on a mission to develop better treatment options for those struggling with alcoholism and other substance use disorders. Named after Claudia Turnbull’s brother, Brett Moore, who died of a drug overdose, B. More is focused on the development of psychedelic medicines that offer the potential to dramatically improve the lives of those for whom current treatment options have proven ineffective. With a long history of partnership with researchers at the NYU School of Medicine, B. More is advancing clinical research to help these individuals and their loved ones live a better tomorrow.

Support our work

Founders

OUR FUNDERS

Together we can change lives

The work of B. More would not be possible without the generous support of our funders: Andrew Mason, Alan Fournier, Cody Swift, George Sarlo, Dr. Bronner’s Soap, Claudia and Carey Turnbull, the Evolve Foundation and others. We invite you to join the effort in making a better tomorrow a reality for those struggling with alcoholism and other substance use disorders.

OUR FOUNDER

Carey Turnbull

Founder & CEO

Carey Turnbull has over a decade of experience in early-stage drug development for half a dozen companies variously as an investor, founder, and CEO. An early philanthropic donor supporting psychedelic science and research, Carey has been at the forefront of driving the psychedelic renaissance and the development of better treatment options for those suffering from psychiatric and neurological disorders.

In addition to his roles as Founder and CEO of B. More and Ceruvia Lifesciences, Carey is the chair of the advisory board to NYU’s Center for Psychedelic Medicine, board member and president of the Heffter Research Institute.

PRINCIPAL INVESTIGATOR

Dr. Michael Bogenschutz

Director, NYU Langone Center for Psychedelic Medicine

Leading B.More’s psilocybin for AUD program clinical trials is Dr. Michael Bogenschutz, Professor of Psychiatry at NYU Grossman School of Medicine and Director of the NYU Langone Center for Psychedelic Medicine.

Considered one of the world’s foremost experts in addiction research, Dr. Bogneschutz has extensive experience in clinical research involving both pharmacologic and psychosocial treatments for substance use disorders and other mental health conditions. His current work is aimed at understanding the health-related effects of psychedelics and related compounds, including their therapeutic effects, safety, and mechanisms of action. Dr. Bogenschutz currently serves as the National Institute on Drug Abuse clinical trials network administrator.

A primary focus of Dr. Bogenschutz’s research is the use of psilocybin to treat alcohol use disorder. In August 2022, Dr. Bogenschutz published the first placebo-controlled trial exploring the treatment of alcohol use disorder (AUD) with psilocybin. The results, published in JAMA psychiatry reported 83% average reduction in heavy drinking among those receiving psilocybin combined with psychotherapy, a dramatic improvement over currently available treatments.